1h agoInvestors.comBEARISH 38Earnings
Why Is GSK PLC ADR ADR (GSK) Stock Moving Today?
By the Top Tier Newswire AI Desk · July 28, 2026 at 9:41 AM ET · reviewed against 27 wire stories
GSK PLC ADR ADR (GSK) is drawing unusual attention today. Our newswire has captured 27 stories on GSK across 10 sources in the last 36 hours, with AI sentiment reading mixed (avg 57/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
GSK stock surged 6.22% to $55.20 in morning trading as the British drugmaker announced a $2.5 billion cost-cutting initiative to fund its drug development pipeline. The company also reported second-quarter earnings that beat estimates and outlined plans to begin 20 or more phase III trials in 2026. The stock opened with a 1.1% gap up and reached an intraday high of $55.62 before settling near $55.10.
What Happened
GSK announced a $2.5 billion savings plan aimed at accelerating its drug pipeline, with annual savings targeted by 2029. The company also declared an interim dividend of $0.4518 per ADS, consistent with prior guidance. Second-quarter results showed adjusted earnings per share of 50.5 pence, exceeding the 46.8 pence estimate, and revenue of £8.41 billion, surpassing the £8.25 billion forecast. CEO Luke Miels emphasized the cost-cutting roadmap as part of his strategy to meet the company’s 2031 sales target. The stock has gained momentum amid positive earnings and strategic clarity.
What The Data Shows
The stock opened at $52.56 and traded as low as $51.32 before rising to a session high. Volume of 0.8 million shares was recorded, slightly below the 3-month daily average. The stock has traded between $36.75 and $61.70 over the past 52 weeks. With a market cap of $102.1 billion, GSK trades at a P/E of 27.7 and offers a dividend yield of 3.49%. The stock had declined 0.8% over the prior eight sessions before today’s sharp reversal.
What To Watch
GSK has no earnings scheduled in the near term, but investors may monitor the breadth of coverage and any further updates on its drug pipeline progress. The company’s ability to meet its 2031 sales target will remain a key focus for analysts.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
GSK by the numbers
7 sessions: -2.00%Coverage: 27 stories / 10 sourcesAI sentiment: 57/100 (mixed)Mkt cap: $102.1BP/E: 27.752w: $36.75 to $61.70
The headlines behind the move
1h agoInvestors.comBEARISH 38Earnings
GSK Stock Tumbles As Vaccine Sales Dip, Dragging On Topline Beat
Third-quarter vaccine sales fell short, outshining a solid topline.
1h agoSeeking AlphaNEUTRAL 50Earnings
GSK plc 2026 Q3 - Results - Earnings Call Presentation
2026-10-28. The following slide deck was published by GSK plc in conjunction with their 2026 Q3 earnings call.
1h agoWSJ BusinessBEARISH 34Earnings
GSK Shares Slide After Vaccine Sales Disappoint
The U.K. drugmaker reported lower-than-expected sales for its shingles vaccine Shingrix, its bestselling product, mainly due to weakness in China.
2h agoQuartzBULLISH 64Earnings
GSK beat Q3 2026 earnings estimates as specialty medicine sales grew
4h agoGuruFocusBULLISH 71Earnings
GSK (GSK) Reports Strong Q3 Sales and Advances Specialty Drug Pipeline
On October 28, 2026, GSK PLC (NYSE: GSK) announced robust third-quarter sales growth alongside key U.S. approvals for three specialty medications, underscoring
4h agoGuruFocusBULLISH 58Earnings
GSK Projects Revenue and Profit Growth Through 2026 Amid Dividend Sustainability Concerns (GSK)
4h agoThe FlyBULLISH 63Earnings
GSK backs 2026 guidance, sees core EPS growth 7%-9%
4h agoThe FlyBULLISH 56Earnings
GSK reports Q3 core EPS 54.6p, up 1% at CER
5h agoGuruFocusBULLISH 58Earnings
GSK Reports 4% Revenue Growth in Q3, Stock Performance Insights
Frequently asked questions
Why is GSK stock moving today?
GSK PLC ADR ADR (GSK) is drawing unusual attention today. Our newswire has captured 27 stories on GSK across 10 sources in the last 36 hours, with AI sentiment reading mixed (avg 57/100). The most recent driver: "GSK Tumbles As Vaccine Sales Dip, Dragging On Topline Beat" (Investors.com).
Is GSK a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of GSK coverage reads 57/100 over 27 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More moves explained today
- Why is AXGN up today (+22.80%)
- Why is GMAB up today (+19.64%)
- Why is FFIV down today (-16.80%)
- Why is DBD down today (-16.08%)
- Why is LSTR down today (-15.58%)
- Why is RAPP down today (-15.38%)
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on GSK: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.